American Journal of Kidney Diseases
Volume 49, Issue 1 , Pages 56-68 , January 2007

Beneficial Impact of Fenoldopam in Critically Ill Patients With or at Risk for Acute Renal Failure: A Meta-Analysis of Randomized Clinical Trials

Received 14 July 2006 ,Accepted 11 October 2006.

References 

  1. Kellum JA, Angus DC. Patients are dying of acute renal failure. Crit Care Med. 2002;30:2156–2157
  2. Metnitz PG, Krenn CG, Steltzer H, et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med. 2002;30:2051–2058
  3. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med. 1998;104:343–348
  4. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: Risk factors, adverse outcomes, and hospital resource utilization (The Multicenter Study of Perioperative Ischemia Research Group). Ann Intern Med. 1998;128:194–203
  5. Hirschberg R, Kopple J, Lipsett P, et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int. 1999;55:2423–2432
  6. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Low-dose dopamine in patients with early renal dysfunction: A placebo-controlled randomised trial. Lancet. 2000;356:2139–2143
  7. Sward K, Valsson F, Odencrants P, Samuelsson O, Ricksten SE. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: A randomized placebo-controlled trial. Crit Care Med. 2004;32:1310–1315
  8. Kien ND, Moore PG, Jaffe RS. Cardiovascular function during induced hypotension by fenoldopam or sodium nitroprusside in anesthetized dogs. Anesth Analg. 1992;74:72–78
  9. Mathur VS, Swan SK, Lambrecht LJ, et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med. 1999;27:1832–1837
  10. Singer I, Epstein M. Potential of dopamine A-1 agonists in the management of acute renal failure. Am J Kidney Dis. 1998;31:743–755
  11. Murphy MB, Murray C, Shorten GD. Fenoldopam: A selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med. 2001;345:1548–1557
  12. Elliott WJ, Weber RR, Nelson KS, et al. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation. 1990;81:970–977
  13. White WB, Halley SE. Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension. Arch Intern Med. 1989;149:870–874
  14. Shusterman NH, Elliott WJ, White WB. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med. 1993;95:161–168
  15. Poinsot O, Romand JA, Favre H, Suter PM. Fenoldopam improves renal hemodynamics impaired by positive end-expiratory pressure. Anesthesiology. 1993;79:680–684
  16. Sehgal CM, Arger PH, Silver AC, et al. Renal blood flow changes induced with endothelin-1 and fenoldopam mesylate at quantitative Doppler US: Initial results in a canine study. Radiology. 2000;219:419–426
  17. Morelli A, Rocco M, Conti G, et al. Effects of short-term fenoldopam infusion on gastric mucosal blood flow in septic shock. Anesthesiology. 2004;101:576–582
  18. Biancofiore G, Della Rocca G, Bindi I, et al. Use of fenoldopam to control renal dysfunction early after liver transplantation. Liver Transpl. 2004;10:986–992
  19. Bove T, Landoni G, Calabro MG, et al. Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: A prospective, double-blind, randomized clinical trial. Circulation. 2005;111:3230–3235
  20. Brienza N, Malcangi V, Dalfino L, et al. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients. Crit Care Med. 2006;34:707–714
  21. Brienza N, Malcangi V, Faconda G, et al. Effects of fenoldopam in early renal dysfunction (ERD) in critically ill patients with chronic hypertension. Minerva Anestesiol. 2003;69(suppl 2):S326A;(abstr)
  22. Caimmi PP, Pagani L, Micalizzi E, et al. Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2003;17:491–494
  23. Della Rocca G, Pompei L, Costa MG, et al. Fenoldopam mesylate and renal function in patients undergoing liver transplantation: A randomized, controlled pilot trial. Anesth Analg. 2004;99:1604–1609
  24. Della Rocca G, Pompei L, Monaco S, Costa MG, Coccia C. Renal protection and liver transplantation. Anesthesiology. 2002;96:415A;(abstr)
  25. Gastaldo P, Launo C. Funzionalità renale durante anestesia generale in chirurgia aortica. Minerva Anestesiol. 2004;70(suppl 2):S42A–S45A(abstr)
  26. Halpenny M, Lakshmi S, O’Donnell A, O’Callaghan-Enright S, O’Connell D, Shorten G. The effects of fenoldopam on coronary conduit blood flow after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2001;15:72–76
  27. Halpenny M, Lakshmi S, O’Donnell A, O’Callaghan-Enright S, Shorten G. Fenoldopam: Renal and splanchnic effects in patients undergoing coronary artery bypass grafting. Anaesthesia. 2001;56:953–960
  28. Halpenny M, Rushe C, Breen P, Cunningham AJ, Boucher-Hayes D, Shorten GD. The effects of fenoldopam on renal function in patients undergoing elective aortic surgery. Eur J Anaesthesiol. 2002;19:32–39
  29. Malcangi V, Dalfino L, Perchiazzi G, Di Venosa C, Pugliese V, Brienza N. Disfunzione renale da shock: Effetto nefroprotettivo del fenoldopam. Minerva Anestesiol. 2004;70(suppl 2):S361A;(abstr)
  30. McCune TR, Wombolt DG, Whelan TV, Thacker LR, Colonna JO. Vasodilatation vs immunotherapy to prevent delayed graft function: Delayed graft function as an indication of immune activation. Int Immunopharmacol. 2005;5:85–92
  31. Morelli A, Ricci Z, Bellomo R, et al. Prophylactic fenoldopam for renal protection in sepsis: A randomized, double-blind, placebo-controlled pilot trial. Crit Care Med. 2005;33:2451–2456
  32. Pittarello D, Bonato R, Falasco G, et al. Studio degli effetti del fenoldopam in pazienti con lieve insufficienza renale sottoposti ad intervento chirurgico. Minerva Anestesiol. 2003;69(suppl 2):S162A;(abstr)
  33. Renzini M, Fontanelli S, Manini E, et al. Fenoldopam in cardiochirurgia. Minerva Anestesiol. 2004;70(suppl 2):S269A;(abstr)
  34. Sheinbaum R, Ignacio C, Safi HJ, Estrera A. Contemporary strategies to preserve renal function during cardiac and vascular surgery. Rev Cardiovasc Med. 2003;4(suppl 1):S21–S28
  35. Sheinbaum R, Safi H, Ignacio C, Carter J, Reyna R. Renal protection and improved outcome by utilization of a DA-1 agonist (fenoldopam) in TAAA repair. Anaesth Analg. 2000;90(suppl):SC31A;(abstr)
  36. Tumlin JA, Finkel KW, Murray PT, Samuels J, Cotsonis G, Shaw AD. Fenoldopam mesylate in early acute tubular necrosis: A randomized, double-blind, placebo-controlled clinical trial. Am J Kidney Dis. 2005;46:26–34
  37. Biondi-Zoccai GGL, Agostoni P, Abbate A, Testa L, Burzotta F. A simple hint to improve Robinson and Dickersin’s highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol. 2005;34:224–225
  38. Higgins JPT, Green S: The Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. Available at: http://www.cochrane.org/resources/handbook/hbook.htm. Accessed October 10, 2005
  39. McGinn TG, Guyatt GH, Cook R, Meade M. Diagnosis: Measuring agreement beyond chance (A Manual for Evidence-Based Clinical Practice). In:  Guyatt G,  Rennie D editor. Users’ Guide to the Medical Literature. Chicago, IL: AMA Press; 2002;p. 461–470
  40. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res. 1993;2:121–145
  41. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
  42. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634
  43. Blanchett DG, Green JA, Nara A, et al. The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure. Clin Pharmacol Ther. 1991;49:449–456
  44. Cicchetti A, Ciccozzi A, Marinangeli F, et al. Use of fenoldopam on renal function in patients undergoing elective aortic surgery: Preliminary results. Minerva Anestesiol. 2004;70(suppl 2):S273A;(abstr)
  45. Donati A, Loggi S, Falcetta S, et al. Effects of corlopam infusion on pHi and Δo2: A randomized controlled clinical trial (Preliminary data). Crit Care. 2003;7(suppl 2):SP050A;(abstr)
  46. Goldberg ME, Cantillo J, Nemiroff MS, et al. Fenoldopam infusion for the treatment of postoperative hypertension. J Clin Anesth. 1993;5:386–391
  47. Hill AJ, Feneck RO, Walesby RK. A comparison of fenoldopam and nitroprusside in the control of hypertension following coronary artery surgery. J Cardiothorac Vasc Anesth. 1993;7:279–284
  48. MacDonald TM, Jeffrey RF, Muir AL, Lee MR. A preliminary study of the dopamine DA1 agonist fenoldopam in the treatment of chronic left ventricular failure due to ischaemic heart disease. Eur J Clin Pharmacol. 1990;38:199–201
  49. MacDonald TM, Jeffrey RF, Muir AL, Lee MR. A preliminary study of fenoldopam in the treatment of chronic left ventricular failure due to ischaemic heart disease. Br J Clin Pharmacol. 1989;27:P662A–P663A(abstr)
  50. Menichetti C, Ornis S, Porcile E, et al. Dopamina vs fenoldopam: Confronto dell’indice di resistenza arteriolare nella valutazione della perfusione renale dopo trapianto. Minerva Anestesiol. 2004;70(suppl 2):S404A–S405A(abstr)
  51. Ramsay MA, Emmett M, Hein T, Tai S, Coultrup S. Perioperative infusion of fenoldopam does not prevent an early decline in GFR in patients undergoing liver transplantation. Anesthesiology. 2004;101:237A;(abstr)
  52. Ramsay MA, Jones C, Emmett M, Hein T, Singer C. The effect of a fenoldopam infusion on postoperative renal function in patients undergoing liver transplantation. Anesthesiology. 2002;96:242A;(abstr)
  53. Vasta C, Criscuolo M, Perez A, Romano I, Limone A, Gravino E. Protezione renale in chirurgia vascolare: Confronto dopamina-fenoldopam. Minerva Anestesiol. 2004;70(suppl 2):S452A;(abstr)
  54. Young JB, Leon CA, Pratt CM, Kingry C, Taylor AA, Roberts R. Intravenous fenoldopam in heart failure: Comparing the hemodynamic effects of dopamine1 receptor agonism with nitroprusside. Am Heart J. 1988;115:378–384
  55. Gombotz H, Plaza J, Mahla E, Berger J, Metzler H. DA1-receptor stimulation by fenoldopam in the treatment of postcardiac surgical hypertension. Acta Anaesthesiol Scand. 1998;42:834–840
  56. Jorkasky DK, Audet P, Shusterman N, et al. Fenoldopam reverses cyclosporine-induced renal vasoconstriction in kidney transplant recipients. Am J Kidney Dis. 1992;19:567–572
  57. Young JB, Leon CA, Pratt CM, Suarez JM, Aronoff RD, Roberts R. Hemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure. J Am Coll Cardiol. 1985;6:792–796
  58. Adams P, Hilleman D, Youngblood F. Renal preservation with fenoldopam in patients undergoing major surgical procedures. Anesth Analg. 2005;100(suppl):S409A;(abstr)
  59. Garwood S, Davis E, Hines RL. Fenoldopam: An effective renal preservation agent in cardiac surgery?. Anesthesiology. 1997;91:154A;(abstr)
  60. Garwood S, Swamidoss CP, Davis EA, Samson L, Hines RL. A case series of low-dose fenoldopam in seventy cardiac surgical patients at increased risk of renal dysfunction. J Cardiothorac Vasc Anesth. 2003;17:17–21
  61. Muruve NA, Tobias J, Arnautovic A, Arnautovic I. Fenoldopam for the prevention of delayed graft function in renal transplantation. 2003;American Transplant Congress :P145-III, (abstr 1389)
  62. Ranucci M, Soro G, Barzaghi N, et al. Fenoldopam prophylaxis of postoperative acute renal failure in high-risk cardiac surgery patients. Ann Thorac Surg. 2004;78:1332–1337
  63. Conger JD, Schultz MF, Miller F, Robinette JB. Responses to hemorrhagic arterial pressure reduction in different ischemic renal failure models. Kidney Int. 1994;46:318–323
  64. Molitoris BA, Sandoval R, Sutton TA. Endothelial injury and dysfunction in ischemic acute renal failure. Crit Care Med. 2002;30(suppl):S235–S240(5)
  65. Stephens CT, Jandhyala BS. Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats. Clin Exp Hypertens. 2002;24:301–313
  66. Okusa MD, Linden J, Huang L, Rieger JM, Macdonald TL, Huynh LP. A(2A) adenosine receptor-mediated inhibition of renal injury and neutrophil adhesion. Am J Physiol Renal Physiol. 2000;279:F809–F818
  67. Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular necrosis (Auriculin Anaritide Acute Renal Failure Study Group). N Engl J Med. 1997;336:828–834
  68. Kellum JA, Decker JM. Use of dopamine in acute renal failure: A meta-analysis. Crit Care Med. 2001;29:1526–1531
  69. Marik PE. Low-dose dopamine: A systematic review. Intensive Care Med. 2002;28:877–883
  70. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: Low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med. 2005;142:510–524
  71. Siragy HM, Felder RA, Peach MJ, Carey RM. Intrarenal DA2 dopamine receptor stimulation in the conscious dog. Am J Physiol. 1992;262:932–938
  72. Huo T, Ye MQ, Healy DP. Characterization of a dopamine receptor (DA2K) in the kidney inner medulla. Proc Natl Acad Sci U S A. 1991;88:3170–3174
  73. Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: A pilot trial in the prevention of contrast nephropathy. Am Heart J. 2002;143:894–903
  74. Linas SL, Whittenburg D, Parsons PE, Repine JE. Ischemia increases neutrophil retention and worsens acute renal failure: Role of oxygen metabolites and ICAM 1. Kidney Int. 1995;48:1584–1591
  75. Molitoris BA, Marrs J. The role of cell adhesion molecules in ischemic acute renal failure. Am J Med. 1999;106:583–592
  76. O’Connell DP, Ragsdale NV, Boyd DG, Felder RA, Carey RM. Differential human renal tubular responses to dopamine type 1 receptor stimulation are determined by blood pressure status. Hypertension. 1997;29:115–122
  77. Kien ND, Moore PG, Jaffe RS. Cardiovascular function during induced hypotension by fenoldopam or sodium nitroprusside in anesthetized dogs. Anesth Analg. 1992;74:72–78
  78. Murphy MB, McCoy CE, Weber RR, Frederickson ED, Douglas FL, Goldberg LI. Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine 1 agonist fenoldopam. Circulation. 1987;76:1312–1318
  79. Kellum JA. Prophylactic fenoldopam for renal protection? (No, thank you, not for me—Not yet at least). Crit Care Med. 2005;33:2681–2683
  80. Zacharias M, Gilmore IC, Herbison GP, Sivalingam P, Walker RJ. Interventions for protecting renal function in the perioperative period. Cochrane Database Syst Rev. 2005;3:CD003590
  81. Kini AS, Mitre CA, Kamran M, et al. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am J Cardiol. 2002;89:999–1002
  82. Madyoon H, Croushore L, Weaver D, Mathur V. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter Cardiovasc Interv. 2001;53:341–345
  83. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: A randomized controlled trial. JAMA. 2003;290:2284–2291
  84. Biondi-Zoccai GG, Agostoni P, Abbate A. Parallel hierarchy of scientific studies in cardiovascular medicine. Ital Heart J. 2003;4:819–820

 Originally published online as doi:10.1053/j.ajkd.2006.10.013 on November 28, 2006.This study is part of a senior training project of the Center for Overview, Meta-analysis, and Evidence-based medicine Training (COMET), based in Milan, Italy (http://it.geocities.com/comet_milano/Home.htm).Support: None. Potential conflicts of interest: None.

PII: S0272-6386(06)01611-8

doi: 10.1053/j.ajkd.2006.10.013

American Journal of Kidney Diseases
Volume 49, Issue 1 , Pages 56-68 , January 2007

Article Tools

* Image Usage & Resolution